MA47508A - Protéines de liaison à cd33, nkg2d et cd16 - Google Patents

Protéines de liaison à cd33, nkg2d et cd16

Info

Publication number
MA47508A
MA47508A MA047508A MA47508A MA47508A MA 47508 A MA47508 A MA 47508A MA 047508 A MA047508 A MA 047508A MA 47508 A MA47508 A MA 47508A MA 47508 A MA47508 A MA 47508A
Authority
MA
Morocco
Prior art keywords
nkg2d
binding proteins
proteins
binding
Prior art date
Application number
MA047508A
Other languages
English (en)
Inventor
Gregory P Chang
Ann F Cheung
William Haney
Bradley M Lunde
Bianka Prinz
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of MA47508A publication Critical patent/MA47508A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
MA047508A 2017-02-20 2018-02-20 Protéines de liaison à cd33, nkg2d et cd16 MA47508A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762461145P 2017-02-20 2017-02-20

Publications (1)

Publication Number Publication Date
MA47508A true MA47508A (fr) 2021-03-17

Family

ID=63169992

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047508A MA47508A (fr) 2017-02-20 2018-02-20 Protéines de liaison à cd33, nkg2d et cd16

Country Status (13)

Country Link
US (1) US20210130471A1 (fr)
EP (1) EP3583131A4 (fr)
JP (2) JP2020510646A (fr)
KR (1) KR20190120775A (fr)
CN (1) CN110573530A (fr)
AU (1) AU2018220734A1 (fr)
BR (1) BR112019017277A2 (fr)
CA (1) CA3054078A1 (fr)
IL (1) IL268790A (fr)
MA (1) MA47508A (fr)
RU (1) RU2019129174A (fr)
SG (1) SG11201907638QA (fr)
WO (1) WO2018152516A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3579848A4 (fr) 2017-02-08 2021-03-03 Dragonfly Therapeutics, Inc. Protéines de fixation multi-spécifiques destinées à l'activation de cellules tueuses naturelles et leurs utilisations thérapeutiques pour traiter le cancer
AU2018220736A1 (en) 2017-02-20 2019-09-05 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
CN112368012A (zh) 2018-02-08 2021-02-12 蜻蜓疗法股份有限公司 靶向nkg2d受体的抗体可变结构域
EA202091977A1 (ru) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
CN113121697B (zh) * 2019-12-31 2023-06-09 周易 Ch3结构域改造诱导形成的异源二聚体及其制备方法和应用
CN115197330B (zh) * 2021-04-14 2023-04-28 广州百暨基因科技有限公司 同时靶向cll1和cd33的嵌合抗原受体及其应用
CN116948029A (zh) * 2022-04-20 2023-10-27 南京融捷康生物科技有限公司 一种包含IgG类Fc区变体的抗体及其用途
WO2024040195A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500108A (ja) * 2000-03-24 2004-01-08 マイクロメット　アーゲー Ｎｋｇ２ｄレセプター複合体のエピトープへの結合部位を含む多機能ポリペプチド
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
CN105001333B (zh) * 2007-12-14 2019-05-17 诺沃—诺迪斯克有限公司 抗人nkg2d抗体及其用途
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
EP2332994A1 (fr) * 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Thérapie trispécifique contre la leucémie myéloïde aiguë
CN111138543A (zh) * 2013-03-15 2020-05-12 Xencor股份有限公司 异二聚体蛋白
EP3008093A1 (fr) * 2013-06-11 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps à domaine unique anti-her2, polypeptides comportant de tels anticorps et leur utilisation pour le traitement du cancer
WO2016025880A1 (fr) * 2014-08-14 2016-02-18 Novartis Ag Traitement du cancer à l'aide du récepteur d'antigène chimérique gfr alpha-4
EP2985294A1 (fr) * 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Molécule d'anticorps de recombinaison et son utilisation pour l'activation des lymphocytes T restreints de cellule cible
EP2990416B1 (fr) * 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Récepteur d'antigène chimérique universel exprimant des cellules immunitaires pour le ciblage de divers antigènes multiples et son procédé de fabrication et son utilisation pour le traitement du cancer, des infections et des troubles auto-immuns
DK3029137T3 (en) * 2014-12-06 2019-04-08 Gemoab Monoclonals Gmbh GENETICALLY MODIFIED PLURI OR MULTIPOTENT STEM CELLS AND USE THEREOF
CN113502270A (zh) * 2015-06-10 2021-10-15 南克维斯特公司 用于治疗癌症的修饰的nk-92细胞
CN109153728A (zh) * 2016-03-21 2019-01-04 埃尔斯塔治疗公司 多特异性和多功能分子及其用途
EP3579848A4 (fr) * 2017-02-08 2021-03-03 Dragonfly Therapeutics, Inc. Protéines de fixation multi-spécifiques destinées à l'activation de cellules tueuses naturelles et leurs utilisations thérapeutiques pour traiter le cancer

Also Published As

Publication number Publication date
BR112019017277A2 (pt) 2020-04-14
RU2019129174A (ru) 2021-03-22
IL268790A (en) 2019-10-31
EP3583131A4 (fr) 2021-03-17
JP2023052214A (ja) 2023-04-11
US20210130471A1 (en) 2021-05-06
CA3054078A1 (fr) 2018-08-23
JP2020510646A (ja) 2020-04-09
AU2018220734A1 (en) 2019-09-12
KR20190120775A (ko) 2019-10-24
EP3583131A1 (fr) 2019-12-25
RU2019129174A3 (fr) 2021-07-02
CN110573530A (zh) 2019-12-13
SG11201907638QA (en) 2019-09-27
WO2018152516A1 (fr) 2018-08-23

Similar Documents

Publication Publication Date Title
MA47508A (fr) Protéines de liaison à cd33, nkg2d et cd16
IL281305A (en) Proteins that bind CD16, NKG2D, and CCR4, EGFR, or PD-L1
MA50255A (fr) Protéines de liaison à nkg2d, cd16, et molécule-1 semblable à la lectine de type c (cll-1)
SG11202010237RA (en) Fusion protein binding to cd47 protein and application thereof
MA47465A (fr) Protéines fixant le bcma, le nkg2d et le cd16
IL270794A (en) NKG2D binding protein, CD16 and ROR1 or ROR2
MA41414A (fr) Protéines de liaison agonistes d' icos
MA43816A (fr) Protéines de liaison inductibles et méthodes d'utilisation
IL268755A (en) HER2, NKG2D, and CD16 binding proteins
ZA201901592B (en) Recombinant binding proteins and their use
MA50942A (fr) Protéines de liaison à l'adn modifiées
DK3275895T3 (da) Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf
MA41313A (fr) Anticorps de liaison de la protéine april modifiés
EP3613771A4 (fr) Molécule de liaison spécifique à protéine lrig-1 et son utilisation
EP3689893A4 (fr) Protéine de liaison à l'immunoglobuline, et support d'affinité mettant en uvre celle-ci
IL268574A (en) proteins that bind psma, nkg2d, and cd16
IL268768A (en) Proteins binding gd2, nkg2d and cd16
IL272374A (en) NKG2D, CD16, and FLT3 binding proteins
EP3689894A4 (fr) Protéine de liaison à l'immunoglobuline, et support d'affinité mettant en uvre celle-ci
EP3445394A4 (fr) Protéines de liaison à alk7 et leurs utilisations
MA42613A (fr) Filtration en profondeur chargée de protéines de liaison à un antigène
SG11202104912SA (en) Fusion protein and use thereof
EP3583132A4 (fr) Protéines de liaison à cd123, nkg2d et cd16
GB201707248D0 (en) Modified complement proteins and uses thereof
MA53284A (fr) Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur